Exovascular application of epigallocatechin-3-O-gallate-releasing electrospun poly(l-lactide glycolic acid) fiber sheets to reduce intimal hyperplasia in injured abdominal aorta

Mi Hee Lee, Byeong Ju Kwon, Min Ah Koo, Eui Hwa Jang, Gyeung Mi Seon, Jongchul Park

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Intimal hyperplasia is an excessive ingrowth of tissue resulting in chronic structural lesions commonly found at sites of atherosclerotic lesions, arterial angioplasty, vascular graft anastomoses, and other vascular abnormalities. Epigallocatechin-3-O-gallate (EGCG) was shown to elicit antioxidant, anti-proliferative, and anti-thrombogenic effects. In this study, we used an electrospinning technique to synthesize EGCG-eluting biodegradable poly(l-lactide glycolic acid) (PLGA) fiber sheets for local delivery of EGCG and investigated the effect of their exovascular application on intimal hyperplasia following balloon-induced abdominal aorta injury in a rabbit experimental model. The morphology of the composite sheets was characterized using scanning electron microscopy and Fourier transform-infrared spectroscopy. EGCG was loaded and dispersed into the PLGA-based electrospun fibers. The EGCG-loaded PLGA sheets exhibited sustained EGCG release following the initial 24 h of burst release in phosphate-buffered saline. In vivo studies demonstrated significant inhibition of intimal hyperplasia following the application of the EGCG-eluting electrospun PLGA fiber sheets, compared with vehicle PLGA controls. In conclusion, our results show that exovascular application of EGCG-eluting PLGA electrospun fiber sheets may provide a useful system for the effective local delivery of drugs for the prevention of intimal hyperplasia.

Original languageEnglish
Article number055010
JournalBiomedical Materials (Bristol)
Volume10
Issue number5
DOIs
Publication statusPublished - 2015 Sep 21

Fingerprint

glycolic acid
Acids
Fibers
Balloons
Electrospinning
Antioxidants
Grafts
Fourier transform infrared spectroscopy
epigallocatechin gallate
dilactide
Phosphates

All Science Journal Classification (ASJC) codes

  • Bioengineering
  • Biomaterials
  • Biomedical Engineering

Cite this

@article{43c74df428074c0d8766c38a7460a343,
title = "Exovascular application of epigallocatechin-3-O-gallate-releasing electrospun poly(l-lactide glycolic acid) fiber sheets to reduce intimal hyperplasia in injured abdominal aorta",
abstract = "Intimal hyperplasia is an excessive ingrowth of tissue resulting in chronic structural lesions commonly found at sites of atherosclerotic lesions, arterial angioplasty, vascular graft anastomoses, and other vascular abnormalities. Epigallocatechin-3-O-gallate (EGCG) was shown to elicit antioxidant, anti-proliferative, and anti-thrombogenic effects. In this study, we used an electrospinning technique to synthesize EGCG-eluting biodegradable poly(l-lactide glycolic acid) (PLGA) fiber sheets for local delivery of EGCG and investigated the effect of their exovascular application on intimal hyperplasia following balloon-induced abdominal aorta injury in a rabbit experimental model. The morphology of the composite sheets was characterized using scanning electron microscopy and Fourier transform-infrared spectroscopy. EGCG was loaded and dispersed into the PLGA-based electrospun fibers. The EGCG-loaded PLGA sheets exhibited sustained EGCG release following the initial 24 h of burst release in phosphate-buffered saline. In vivo studies demonstrated significant inhibition of intimal hyperplasia following the application of the EGCG-eluting electrospun PLGA fiber sheets, compared with vehicle PLGA controls. In conclusion, our results show that exovascular application of EGCG-eluting PLGA electrospun fiber sheets may provide a useful system for the effective local delivery of drugs for the prevention of intimal hyperplasia.",
author = "Lee, {Mi Hee} and Kwon, {Byeong Ju} and Koo, {Min Ah} and Jang, {Eui Hwa} and Seon, {Gyeung Mi} and Jongchul Park",
year = "2015",
month = "9",
day = "21",
doi = "10.1088/1748-6041/10/5/055010",
language = "English",
volume = "10",
journal = "Biomedical Materials (Bristol)",
issn = "1748-6041",
publisher = "IOP Publishing Ltd.",
number = "5",

}

Exovascular application of epigallocatechin-3-O-gallate-releasing electrospun poly(l-lactide glycolic acid) fiber sheets to reduce intimal hyperplasia in injured abdominal aorta. / Lee, Mi Hee; Kwon, Byeong Ju; Koo, Min Ah; Jang, Eui Hwa; Seon, Gyeung Mi; Park, Jongchul.

In: Biomedical Materials (Bristol), Vol. 10, No. 5, 055010, 21.09.2015.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Exovascular application of epigallocatechin-3-O-gallate-releasing electrospun poly(l-lactide glycolic acid) fiber sheets to reduce intimal hyperplasia in injured abdominal aorta

AU - Lee, Mi Hee

AU - Kwon, Byeong Ju

AU - Koo, Min Ah

AU - Jang, Eui Hwa

AU - Seon, Gyeung Mi

AU - Park, Jongchul

PY - 2015/9/21

Y1 - 2015/9/21

N2 - Intimal hyperplasia is an excessive ingrowth of tissue resulting in chronic structural lesions commonly found at sites of atherosclerotic lesions, arterial angioplasty, vascular graft anastomoses, and other vascular abnormalities. Epigallocatechin-3-O-gallate (EGCG) was shown to elicit antioxidant, anti-proliferative, and anti-thrombogenic effects. In this study, we used an electrospinning technique to synthesize EGCG-eluting biodegradable poly(l-lactide glycolic acid) (PLGA) fiber sheets for local delivery of EGCG and investigated the effect of their exovascular application on intimal hyperplasia following balloon-induced abdominal aorta injury in a rabbit experimental model. The morphology of the composite sheets was characterized using scanning electron microscopy and Fourier transform-infrared spectroscopy. EGCG was loaded and dispersed into the PLGA-based electrospun fibers. The EGCG-loaded PLGA sheets exhibited sustained EGCG release following the initial 24 h of burst release in phosphate-buffered saline. In vivo studies demonstrated significant inhibition of intimal hyperplasia following the application of the EGCG-eluting electrospun PLGA fiber sheets, compared with vehicle PLGA controls. In conclusion, our results show that exovascular application of EGCG-eluting PLGA electrospun fiber sheets may provide a useful system for the effective local delivery of drugs for the prevention of intimal hyperplasia.

AB - Intimal hyperplasia is an excessive ingrowth of tissue resulting in chronic structural lesions commonly found at sites of atherosclerotic lesions, arterial angioplasty, vascular graft anastomoses, and other vascular abnormalities. Epigallocatechin-3-O-gallate (EGCG) was shown to elicit antioxidant, anti-proliferative, and anti-thrombogenic effects. In this study, we used an electrospinning technique to synthesize EGCG-eluting biodegradable poly(l-lactide glycolic acid) (PLGA) fiber sheets for local delivery of EGCG and investigated the effect of their exovascular application on intimal hyperplasia following balloon-induced abdominal aorta injury in a rabbit experimental model. The morphology of the composite sheets was characterized using scanning electron microscopy and Fourier transform-infrared spectroscopy. EGCG was loaded and dispersed into the PLGA-based electrospun fibers. The EGCG-loaded PLGA sheets exhibited sustained EGCG release following the initial 24 h of burst release in phosphate-buffered saline. In vivo studies demonstrated significant inhibition of intimal hyperplasia following the application of the EGCG-eluting electrospun PLGA fiber sheets, compared with vehicle PLGA controls. In conclusion, our results show that exovascular application of EGCG-eluting PLGA electrospun fiber sheets may provide a useful system for the effective local delivery of drugs for the prevention of intimal hyperplasia.

UR - http://www.scopus.com/inward/record.url?scp=84947976137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947976137&partnerID=8YFLogxK

U2 - 10.1088/1748-6041/10/5/055010

DO - 10.1088/1748-6041/10/5/055010

M3 - Article

C2 - 26391656

AN - SCOPUS:84947976137

VL - 10

JO - Biomedical Materials (Bristol)

JF - Biomedical Materials (Bristol)

SN - 1748-6041

IS - 5

M1 - 055010

ER -